New mesothelioma treatment combines immunotherapy and targeted radiotherapy

Memorial Sloan Kettering in New York is now recruiting relapsed mesothelioma patients into a safety and efficacy study of stereotactic body radiotherapy (SBRT) and the immunotherapy drug avelumab. The new trial is based on the idea that radiotherapy may boost the immune system’s anti-mesothelioma response and that avelumab may enhance the effect.
Surviving Mesothelioma